|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Low density of CD3+ \CD46 and CD86 cells isassociated with increased risk of relapse in squamous cell cervical cancer 显示文摘 | Nedergaard BS Ladekarl M Thomsen HF | 2007 | Br J Cancer2007，97，8： | 1 |
| 2 | Low density of CD3^+ , CD4^ + and CD8 ^+ ceils is associated with increased risk of relapse insquamous cell cervical cancer 显示文摘 | Nedergaard BS Ladekarl M Thomsen HF | 2007 | Br J Cancer2007，97，8： | 1 |
| 3 | Iw density of CD3, CD4 and CD8 cells is associated with increased risk of relapse in squamous cell cervical cancer显示文摘 | Nedergaard BS Ladekarl M Thomsen HF | 2007 | Br J Cancer2007，97，8： | 1 |
| 4 | Effectof evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-c lowering in patients withhypercholesterolemia: the LAPLACE-2 randomized clinicaltrial 显示文摘 | Robinson JG Nedergaard BS Rogers WJ | 2014 | J Am Med Assoc2014，311，18： | 1 |
| 5 | Effect of evolocumab or ezetimibe added to moderate-or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia:the LAPLACE-2 randomized clinical trial显示文摘 | ROBINSON JG NEDERGAARD BS ROGERS WJ | 2014 | JAMA2014，311，18： | 1 |
| 6 | The LAPLACE-2 trial: a phase 3, double-blind, randomized, placebo and ezetimibe controlled, multi- 'i! center study to evaluate safety, tolerability and efficacy of evolocumab ( AMG 145 ) in combination with statin therapy in subjects with primary hypercholester- olemia and mixed dyslipidemia显示文摘 | Robinson JG Rogers WJ Nedergaard BS | 2014 | Clin Cardiol2014，37，4： | 1 |
| 7 | Low density of CD3+, CD4+ and CD8+ cells is associated with in creased risk of relapse in squamous cell cervical cancer 显示文摘 | Nedergaard BS Ladekarl M Thomsen HF | 2007 | Br J Cancer2007，97，8： | 1 |
| 8 | Low density of CD3 + , CD4 + and CD8 + cells is associated with increased risk of relapse in squamous cell cervical cancer显示文摘 | Nedergaard BS Ladekarl M Thomsen HF | 2007 | Br J Cancer2007，97，8： | 1 |
| 9 | Rationale and design of LAPLACE-2:a phase 3,randomized,doubleblind,placebo-and ezetimibe-controlled trial evaluating the efficacy and safety of evolocumab in subjects with hypercholesterolemia on background statin therapy显示文摘 | Robinson JG Rogers WJ Nedergaard BS | 2014 | Clin Cardiol2014，4，37： | 1 |
| 10 | Effect of evolocum ab orezetimibe added to moderate-or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia:the LAPLACE-2 randomized clinical trial显示文摘 | Robinson JG Nedergaard BS Rogers WJ | 2014 | JAMA2014，311，18： | 1 |
| 11 | Effect of evolocumab or ezetimibe added to moderateor high-intensity statin therapy on LDL-C lowering in pa- tients with hypereholesterolemia 显示文摘 | Robinson JG Nedergaard BS Rogers WJ | 2014 | JAMA2014，311，18： | 1 |
| 12 | Effect of evolocumab or ezetimnibe added to moderate-or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia:the LAPLACE-2 randomized clinical trial显示文摘 | Robinson JG Nedergaard BS Rogers WJ | 2014 | JAMA2014，311，： | 1 |
| 13 | Effect of Evolocumab or Ezetimibe Added to Moderate- or High- Intensity Statin Therapy on LDL-C Lowering in Patients With Hypercholesterolemia The LAPLACE-2 Rando- mized Clinical Trial显示文摘 | Robinson JG Nedergaard BS Rogers WJ | 2014 | JAMA2014，311，18： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员